Skip to content
Finger pointing brain scan

QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy that Restores UNC13A Function in ALS and FTD

QurAlis Corporation (“QurAlis”) today announced that it has entered into an exclusive license agreement with Eli Lilly and Company (“Lilly”) in which QurAlis is granting Lillly global rights to develop and commercialize QRL-204, a potentially best-in-class splice-switching antisense oligonucleotide (ASO) designed to restore UNC13A function in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases.

Scientist in a lab

Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the publication of the results of preclinical studies in ACS Chemical Neuroscience that validate the decisions to pursue RE104, a proprietary, patented prodrug of 4-OH-DiPT as a potential therapeutic in depressive disorders.

people signing

Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the close of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo.

Scientists looking at microscope.

Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry

Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.

Mitsui Invests in E12 Ventures, a US-based Venture Capital Fund

Mitsui Invests in E12 Ventures, a US-based Venture Capital Fund

Mitsui & Co., Ltd. (“Mitsui”, Head Office: Tokyo, President and CEO: Kenichi Hori), together with The Norinchukin Bank (President and CEO: Kazuto Oku), Mitsubishi Pencil Company, Limited (President: Shigehiko Suhara), and Nitto Denko Corporation (President: Hideo Takasaki) (hereinafter collectively “the Limited Partners”), announced its capital commitment to E12 Venture Capital Fund I, L.P. (“E12 Fund I”) upon its final closing.

Back To Top
Search